Baseline patient characteristics
| . | POM+LoDEX (n = 113) . | POM alone (n = 108) . | Total (N = 221) . |
|---|---|---|---|
| Median age, y (range) | 64 (34-88) | 61 (37-88) | 63 (34-88) |
| Age distribution, % | |||
| ≤65 y | 55 | 64 | 59 |
| >65 y | 45 | 36 | 41 |
| ≤75 y | 88 | 88 | 88 |
| >75 y | 12 | 12 | 12 |
| Male, % | 55 | 53 | 54 |
| MM stage, % | |||
| I | 7 | 7 | 7 |
| II | 26 | 27 | 26 |
| III | 67 | 66 | 67 |
| ECOG performance status score, % | |||
| 0 | 28 | 22 | 25 |
| 1 | 60 | 66 | 63 |
| 2 | 12 | 10 | 11 |
| 3 | 0 | 2 | 1 |
| Cytogenetic profile, % | |||
| High-risk* | 27 | 28 | 27 |
| Standard-risk | 50 | 40 | 45 |
| Missing data | 23 | 32 | 28 |
| Median number of prior therapies (range) | 5 (2-13) | 5 (1-12) | 5 (1-13) |
| Number of prior therapies, % | |||
| ≤2 | 5 | 5 | 5 |
| >2 | 95 | 95 | 95 |
| Prior therapies, % | |||
| LEN and BORT | 100 | 100 | 100 |
| DEX | 99 | 99 | 99 |
| Thalidomide | 67 | 67 | 67 |
| Stem cell transplantation | 74 | 76 | 75 |
| CFZ | 17 | 29 | 23 |
| Prior thalidomide exposure, % | |||
| Yes | 67 | 67 | 67 |
| No | 33 | 33 | 33 |
| LEN as last prior therapy, % | 39 | 31 | 35 |
| Refractory to LEN, %† | 78 | 80 | 79 |
| Refractory to BORT, %‡ | 71 | 70 | 71 |
| Refractory to both LEN and BORT, %§ | 62 | 61 | 62 |
| . | POM+LoDEX (n = 113) . | POM alone (n = 108) . | Total (N = 221) . |
|---|---|---|---|
| Median age, y (range) | 64 (34-88) | 61 (37-88) | 63 (34-88) |
| Age distribution, % | |||
| ≤65 y | 55 | 64 | 59 |
| >65 y | 45 | 36 | 41 |
| ≤75 y | 88 | 88 | 88 |
| >75 y | 12 | 12 | 12 |
| Male, % | 55 | 53 | 54 |
| MM stage, % | |||
| I | 7 | 7 | 7 |
| II | 26 | 27 | 26 |
| III | 67 | 66 | 67 |
| ECOG performance status score, % | |||
| 0 | 28 | 22 | 25 |
| 1 | 60 | 66 | 63 |
| 2 | 12 | 10 | 11 |
| 3 | 0 | 2 | 1 |
| Cytogenetic profile, % | |||
| High-risk* | 27 | 28 | 27 |
| Standard-risk | 50 | 40 | 45 |
| Missing data | 23 | 32 | 28 |
| Median number of prior therapies (range) | 5 (2-13) | 5 (1-12) | 5 (1-13) |
| Number of prior therapies, % | |||
| ≤2 | 5 | 5 | 5 |
| >2 | 95 | 95 | 95 |
| Prior therapies, % | |||
| LEN and BORT | 100 | 100 | 100 |
| DEX | 99 | 99 | 99 |
| Thalidomide | 67 | 67 | 67 |
| Stem cell transplantation | 74 | 76 | 75 |
| CFZ | 17 | 29 | 23 |
| Prior thalidomide exposure, % | |||
| Yes | 67 | 67 | 67 |
| No | 33 | 33 | 33 |
| LEN as last prior therapy, % | 39 | 31 | 35 |
| Refractory to LEN, %† | 78 | 80 | 79 |
| Refractory to BORT, %‡ | 71 | 70 | 71 |
| Refractory to both LEN and BORT, %§ | 62 | 61 | 62 |
CFZ, carfilzomib; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease.
High-risk cytogenetic profiles defined as del(17p13) and/or t(4p16/14q32).
Defined as patients who experienced PD during or within 60 d (measured from the last dose) of completing treatment with LEN.
Defined as patients who experienced PD during or within 60 d (measured from the last dose) of completing treatment with BORT.
Defined as patients who experienced PD during or within 60 d (measured from the last dose) of completing treatment with LEN and BORT.